Skip to main content

Table 1 Risk factors associated with mortality among COVID-19 patients

From: D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study

  Univariable OR (95% CI) P value Multivariable OR (95% CI) P value
Age (years)a 1.08 (1.03~1.14) 0.004 1.04 (0.98~1.10) 0.187
Female (vs male) 2.32 (0.83~6.48) 0.109 - -
Comorbidity present (vsnot present)
Hypertension 1.58 (0.58~4.31) 0.374 - -
Diabetes mellitus 2.83 (0.92~8.67) 0.069 - -
SOFA scorea 2.00 (1.50~2.69) 0.000 1.44 (0.89~2.33) 0.134
qSOFA scorea 4.47 (2.22~8.99) 0.000 2.43 (0.87~6.77) 0.091
ISTH-DIC score
0–4 1 (ref) -   
≥ 5 24.43 (3.77~158.31) 0.000 1.40 (0.05~36.97) 0.84
CURB-65 score
0–1 1 (ref) -   
2 7.59 (2.20~26.25) 0.001 1.31 (0.26~6.71) 0.743
≥ 3 14.43 (3.89~53.56) 0.000 0.86 (0.09~8.05) 0.895
Lymphocyte count (109/L)
< 1.0 9.85 (2.54~37.80) 0.001 1.94 (0.24~15.57) 0.533
≥ 1.0 1 (ref) -   
Alanine aminotransferase (U/L)
≤ 40 U/L 1 (ref) - - -
> 40 U/L 0.48 (0.13~1.72) 0.259 - -
eGFR (ml/[min*1.73m2])
< 90 1.67 (0.60~4.67) 0.326 - -
≥ 90 1 (ref) - - -
Creatine kinase (U/L)
≤ 198 1 (ref) - - -
> 198 2.18 (0.58~8.25) 0.250 - -
D-dimer (mg/L)
< 1 1 (ref) - 1 (ref) -
1–2 2.48 (0.15~40.47) 0.524 2.21 (0.12~38.61) 0.612
> 2 24.43 (3.16~189.00) 0.002 10.17 (1.10~94.38) 0.041
Anticoagulation therapy
No 1 (ref) - -  
Yes 0.95(0.34~2.67) 0.93 -  
  1. a Per 1-unit increase